Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
$14.10
-$0.27(-3.80%)
At close: 4:00 PM EST
$14.10
-$0.27(-3.80%)
Day’s Range― - ―
52-Week Range$4.27 - $17.89
Previous CloseN/A
Volume480.81K
Average Volume (3M)1.92M
Market Cap
$2.58B
Enterprise Value$1.79B
Total Cash (Recent Filing)$212.77M
Total Debt (Recent Filing)$213.64M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Feb 17, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding152,273,910
10 Day Avg. Volume1,640,448
30 Day Avg. Volume1,920,434
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)4.93
P/FCF Ratio-8.93
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue7.09
Enterprise Value/Gross Profit9.87
Enterprise Value/Ebitda-31.35
Forecast
1Y Price Target
$18.57Price Target Upside31.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Flow And Financial HealthThe MRD business segment turned cash flow positive, indicating strong financial health.
Financial PerformanceAdaptive Biotechnologies met the mark for key metrics in the third quarter, including accelerated clonoSEQ volume growth and higher ASPs.
Market PerformanceADPT's stock has nearly tripled YTD, demonstrating strong market performance and investor confidence.
Bears Say
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $4.27 and its highest was $17.89 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $2.58B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Feb 17, 2026 which is in 91 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Nov 05, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.207.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.18.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 152,273,910 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -11.541%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.57 (31.70% Upside)
$18.57 (31.70% Upside)
Hedge Fund Trend
Decreased
By 699.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
280.98%
12-Months-Change
Fundamentals
Return on Equity
-37.18%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Company Deck
ADPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in MRD business profitability, improved gross margins, and a solid cash position, with a raised full-year guidance. However, there were challenges in Immune Medicine revenue and uncertainties in regulatory acceptance of MRD as an endpoint.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$18.57
▲(31.70% Upside)
Technical Analysis
Immunovant
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
4.36% Insiders
20.11% Mutual Funds
0.22% Other Institutional Investors
55.79% Public Companies and
Individual Investors